Prognostic Significance of Nuclear β-Catenin Expression in Patients with Colorectal Cancer from Iran

Ehsan Nazemalhosseini Mojarrad 1; Seyed Mohammad Hossein Kashfi 2; Hanieh Mirtalebi 2; Shohre Almasi 1; Vahid Chaleshi 2; Roya Kishani Farahani 2; Peyman Tarban 2; Mahsa Molaei 4; Mohammad Reza Zali 1; Peter J.K. Kuppen 3

1 Gastroenterology and Liver Disease Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Basic and Molecular Epidemiology of Gastroenterology Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3 Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands
4 Corresponding Author: Mahsa Molaei, Gastroenterology and Liver Disease Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran. Tel: +98-2122432525, Fax: +98-2122432514, E-mail: molaemahsaz@gmail.com

Received: July 26, 2014; Revised: November 22, 2014; Accepted: March 20, 2015

Background: Beta catenin plays a key role in cancer tumorigenesis. However, its prognostic significance in patients with colorectal cancer (CRC) remains controversial. It has been demonstrated that 90% of all tumors have a mutation in individual components of multiple oncogenes in Wnt/β-catenin pathway. Accumulation of nuclear β-catenin in cytoplasm leads to uncontrolled cell proliferation. Thus, nuclear β-catenin accumulation may be a valuable biomarker associated with invasion, metastasis and poor prognosis of CRC.

Objectives: In this study the prognostic value of beta catenin expression in 165 Iranian CRC patients was evaluated.

Patients and Methods: In this cross sectional retrospective study immunohistochemistry analyses of formalin-fixed paraffin-embedded (FFPE) tumor tissues were performed to characterize the expression of nuclear β-catenin in a series of 165 Iranian patients with colorectal carcinoma. Heat-induced antigen retrieval using the microwave method was applied for all staining procedures. Staining was scored independently by two observers, and a high level of concordance (90%) was achieved. Statistical analysis was done using the SPSS software for Windows, version 13.0.0 (SPSS Inc., Chicago, IL). Two-tailed P < 0.05 was considered statistically significant.

Results: The patients consisted of 85 males and 80 females. Eighty-eight patients had primary tumor of the rectum and sigmoid, while 77 patients had primary tumor of the colon. The mean period of follow-up was 47.2 ± 10 months and the median period of follow-up was 38 months (range 6 - 58) for each patient. Of 165 tumors, 32 tumors (19.39 %) showed expression of β-catenin in cytoplasm. The expression of nuclear β-catenin was significantly higher in tumors than patients with negative nuclear β-catenin expression (P = 0.010). Univariate and multivariate analysis showed that tumors with β-catenin expression had a poorer prognosis compared to tumors without β-catenin expression.

Conclusions: According to our findings, the distribution of nuclear β-catenin expression is a poor prognostic marker in patients with colon cancer.

Keywords: Beta Catenin; Colorectal Cancer; Prognostic Biomarkers; Neoplasm Staging

1. Background

Colorectal cancer (CRC) is a widespread malignancy in most countries, with a high incidence in Asian countries (1). In the Iranian population, approximately 1130 CRC-related deaths were registered in 2006 (2). Several studies have evaluated the burden of CRC in its sporadic and familial types in the Iranian population (3-5). Transformation of normal colonic mucosa to invasive cancer requires both accumulations of genetic and epigenetic alterations (6).

These alterations in CRC have a distinct molecular pathway: chromosomal instability (CIN), microsatellite instability (MSI) and CpG Island methylator phenotype (CIMP) (6). In the CIN pathway, karyotypic abnormalities, aneuploidy, loss of heterozygosity and certain mutations are important events (7). Throughout the CIN pathway, several tumor suppressor genes and oncogenes are mutated. Among them, adenomatous polyposis coli (APC), β-catenin, Axin and GSK3β genes, which are the members of the Wnt signaling pathway, play an important role in colorectal cancer tumorigenesis (8, 9). In CRC, 90% of all tumors have a mutation in individual components of multiple oncogenes in Wnt/β-catenin pathway (9). Furthermore, β-catenin is a 92-kDa cellular protein, identified as a protein associated with E-cadherin in maintaining cellular adhesion (10). Also, β-catenin has an independent role in the Wnt signal transduction pathway. Mutation in
components of the APC complex leads to increased level of cytoplasmic β-catenin and its translocation to the nucleus (11). Accumulation of nuclear β-catenin in the cytoplasm acts as a transcription factor and binds to T-Cell Factor/Lymphoid Enhancer Factor (TCF/LEF), which leads to activation of target genes including: CyclinD1, c-Myc, CD44 and Survivin, and at the end it results in uncontrolled cell proliferation in tumor cells (12).

Thus, nuclear β-catenin accumulation may be a valuable biomarker associated with invasion, metastasis and poor prognosis of CRC (13).

2. Objectives

The aim of this study was to evaluate nuclear β-catenin expression as a predictor of clinical outcome in Iranian patients with CRC.

3. Patients and Methods

3.1. Patient Samples and Tumor Data

This retrospective cross sectional study was performed on 165 randomly selected Iranian patients with primary colorectal cancer, who had undergone surgical resection of adenocarcinoma and been referred to the gastroenterology and liver diseases research center of Shahid Beheshti university of medical sciences, Tehran, Iran from 2005 until 2010.

The inclusion criteria consisted of a pathological diagnosis of primary CRC and having undergone a surgical operation for treatment and availability of the patient’s formalin-fixed paraffin-embedded sample. On the other hand, patients with Familial Adenomatous Polyposis coli (FAP) and patients without formalin-fixed paraffin-embedded (FFPE) were excluded from the study.

Informed consent was obtained from all patients, or their relatives. Demographic and clinical information was registered prospectively and recorded in a database; this information included age, sex, personal and family medical history, tumor location, tumor, lymph nodes, and metastasis (TNM) stage, tumor differentiation and MSI status. Tumor tissue specimens obtained from the resected tumor were embedded in paraffin blocks according to standard procedures. Microsatellite instability status in tumors was classified as microsatellite instability high (MSI-H), Microsatellite instability low (MSI-L) and MS-L. The TNM staging system was applied to determine the severity of disease and the local or distant extent of disease spread. The TNM staging system of the American joint committee on cancer (AJCC) is the preferred and standard staging system for CRC. Approval of the study was obtained from the regional ethics committee on 7th of July 2004 with code number 681.

3.2. Immunohistochemical Procedures

Formalin-fixed, paraffin-embedded blocks with tumor tissue were sectioned at a nominal size (3 to 5 micrometers thick). Heat-induced antigen retrieval using the microwave method was applied for all staining procedures. In details, the blocks were deparaffinized and processed as follows: 1) the samples were preserved in an oven at 37°C for 24 hours, 2) rinsed with 100% xylol, 100%, 85% and 75% ethanol, and distilled water, 3) exposed to 10% H2O2, and methanol at a ratio of 1 : 9 for 15 minutes and then rinsed with deionized water, 4) placed in citrate buffered solution (pH = 6) for 24 minutes in a microwave with 800 W and then rinsed with tris-buffered saline (TBS), 5) blocking serum was added to the slides for 15 minutes, and then dried, 6) β-catenin antibodies (monoclonal mouse anti-human β-catenin Dako M3539) were added followed by 45 minutes of incubation at room temperature, and then rinsed with TBS, 7) Envision + visualization system (Dako) was added, followed by 30 minutes of incubation, 8) DAB was added, followed by 10 minutes of incubation, 9) the final samples were rinsed with water, dehydrated in alcohol, and counterstained with hematoxylin. The slides were evaluated by light microscopy. Staining was scored independently by two observers and a high level of concordance (90%) was achieved. All slides were independently reviewed twice and intra-observer disagreements (< 10%) were reviewed a third time followed by a conclusive judgment. Evaluation of nuclear β-catenin expression was performed using a quantitative scale. Nuclear β-catenin staining in the tumor cells was categorized as either positive or negative, whereas the intensity of staining was not considered. The entire tissue sections for each tumor were scanned to estimate the mean value of β-catenin positive nuclei using a two-graded scale (negative, < 5%); (positive, > 5%). Nuclear β-catenin staining was evaluated on whole standard tissue sections from the colon carcinomas. Staining was assessed considering the front of tumor invasion (tumor margin) and the tumor center.

3.3. Statistical Analysis

Statistical analysis was performed using the SPSS software program for Windows, version 13.0.0 (SPSS Inc., Chicago, IL). Comparison of variables was performed using Pearson’s chi-square test, Fisher’s exact test, or the Mann-Whitney U test, depending on the nature of the data. Two-tailed P < 0.05 was considered statistically significant. Relationships among the clinicopathological factors and β-catenin were analyzed using the chi-square test. For survival analyses, the following variables were assessed: age, sex, location of the tumor (colon versus rectum), tumor-node-metastasis stage, and grade of differentiation (well / moderate versus poor), use of chemotherapy, age at diagnosis, family history, and MSI. Overall survival analyses were done through a Cox proportional hazard function for both univariate and multivariate analyses, and Kaplan-Meier (log-rank test) curves were plotted. Significance for all statistics were recorded if P < 0.05.
Overall survival was defined as the time from histopathological diagnosis to death from any cause. Patients were followed up until July 2011. Patients who died due to reasons unrelated to colorectal cancer were censored at the time of death and were excluded from the analysis.

4. Results

The patients consisted of 85 males and 80 females. Eighty-eight patients had primary tumor of the rectum and sigmoid, and 77 patients had primary tumor of the colon (ascending, transverse and descending). The mean period of follow-up was 47.2 ± 10 months for each patient and the median period of follow-up was 38 months.

In the present study 32 out of 165 tumors (19.39 %) expressed nuclear β-catenin and 133 (80.6 %) were negative for nuclear β-catenin expression. The clinicopathological differences between nuclear β-catenin negative and nuclear β-catenin positive tumors are shown in Table 1.

Table 1. Demographic and Clinicopathological Features of the Colorectal Cancer Patients a,b

| Variables               | Total | Positive c | Negative c | P Value |
|-------------------------|-------|------------|------------|---------|
| Patients                | 165   | 32 (19.4)  | 133 (80.6) |         |
| Mean age                |       | 49.25      | 56.24      | 0.010   |
| Gender                  |       |            |            | 0.077   |
| Male                    | 85 (51.5) | 12 (37.5)  | 73 (54.9)  |         |
| Female                  | 80 (48.5) | 20 (62.5)  | 60 (62.5)  |         |
| Location of tumor       |       |            |            | 0.024   |
| Ascending colon         | 24 (14.5) | 10 (31.3)  | 14 (10.5)  |         |
| Transverse colon        | 26 (15.8) | 2 (6.3)    | 24 (18.0)  |         |
| Descending colon        | 27 (16.4) | 4 (12.5)   | 23 (17.3)  |         |
| Sigmoid                 | 25 (15.2) | 3 (9.4)    | 22 (16.5)  |         |
| Rectum                  | 63 (38.2) | 13 (40.6)  | 50 (37.6)  |         |
| Differentiation         |       |            |            | 0.122   |
| Poorly                  | 18 (10.9) | 1 (3.1)    | 17 (12.8)  |         |
| Moderately              | 46 (27.9) | 7 (21.9)   | 39 (29.3)  |         |
| Well                    | 77 (46.7) | 16 (50.0)  | 61 (45.9)  |         |
| Unknown                 | 24 (14.5) | 8 (25.0)   | 16 (12.0)  |         |
| TNM stage               |       |            |            | 0.452   |
| I                       | 13 (7.9)   | 1 (3.1)    | 12 (9.0)   |         |
| II                      | 75 (45.5)  | 13 (40.6)  | 62 (46.6)  |         |
| III                     | 60 (36.4)  | 13 (40.6)  | 47 (35.3)  |         |
| IV                      | 17 (10.3)  | 5 (15.6)   | 12 (9.0)   |         |
| Family history          |       |            |            | 0.402   |
| No                      | 123 (74.5) | 22 (68.8)  | 101 (73.9) |         |
| Yes                     | 42 (25.5)  | 10 (31.3)  | 32 (24.1)  |         |
| Vital status            |       |            |            | 0.008   |
| Living                  | 135 (81.8) | 21 (65.6)  | 114 (85.7) |         |
| Deceased                | 30 (18.2)  | 11 (34.4)  | 19 (14.3)  |         |
| Age of diagnosis        |       |            |            | 0.004   |
| < 50                    | 81 (49.1)  | 23 (71.9)  | 58 (43.6)  |         |
| > 50                    | 84 (50.9)  | 9 (28.1)   | 75 (56.4)  |         |
| MSI status              |       |            |            | 0.001   |
| MSS                     | 102 (61.8)| 18 (56.3)  | 84 (63.2)  |         |
| MSL                     | 38 (23.0)  | 3 (9.4)    | 35 (26.3)  |         |
| MSH                     | 25 (15.2)  | 11 (34.4)  | 14 (10.5)  |         |

a Abbreviations: MSS, Microsatellite stable; MSI-L, Microsatellite instability low; MSI-H, Microsatellite instability High.
b Data are presented as N (%).
c Positive/negative expression of nuclear β-catenin.
Patients in the nuclear β-catenin positive group were found to be younger than patients in the nuclear β-catenin negative group (mean age of 49.25 and 56.24 years, respectively), and interestingly this difference was statistically significant (P = 0.010).

We also found that the nuclear β-catenin positive group with rectum tumors had a younger age of diagnosis (P = 0.004) than the nuclear β-catenin negative group. We observed that the tumors in patients with positive β-catenin expression were predominantly located in the rectum.

In this study, distribution of MSI status differed between patients with nuclear β-catenin positive and negative tumors, and the difference was significant (P = 0.001).

The expression level of β-catenin was 56.3% in MSS, 9.4% in MSI-L and 34.4% in MSI-H tumors. We found no significant differences between patients with nuclear β-catenin positive and negative tumors regarding gender, TNM staging and family history, however stage II and III were more frequent in β-catenin positive CRCs in comparison with β-catenin negative tumors, yet this difference was not statically significant.

All the characteristics with prognostic value in overall survival were entered in the cox model (univariate and multivariate analysis) including age at diagnostic, tumor stage, MSI status, family history and β-catenin expression. We did not find any significant correlation between overall survival and the aforementioned prognostic factors, except for β-catenin status.

Univariate and multivariate analysis showed that tumors with nuclear β-catenin expression have a poor prognosis compared with tumors without nuclear β-catenin expression (Table 2).

Overall survival curves relative to β-catenin expression were obtained for all colorectal cancer patients. Tumors with nuclear β-catenin expression had a poorer prognosis compared to tumors with negative expression for nuclear β-catenin (P = 0.012; Figure 1).

### Table 2. Univariate and Multivariate Cox Regression Analysis of Possible Prognostic Variables and Parameters That Correlate With Overall Survival

| Variables                  | Univariate Analysis | Multivariate Analysis |
|----------------------------|---------------------|-----------------------|
|                            | Hazard Ratio for Death | P Value | Hazard Ratio for Death | P Value |
| Gender                     |                      |                      |
| Female                     | 1 ref.               | 1 ref.               |
| Male                       | 1.356 [0.659 - 2.792] | 0.408 | 0.628 [0.267 - 1.476] | 0.286 |
| Location of tumor          |                      |                      |
| Rectum                     | 1 ref.               | 1 ref.               |
| Ascending colon            | 1.482 [0.517 - 4.251] | 0.464 | 1.347 [0.381 - 4.754] | 0.644 |
| Transverse colon           | 0.532 [0.374 - 1.626] | 0.268 | 0.547 [0.157 - 1.908] | 0.344 |
| Descending colon           | 0.363 [0.103 - 1.278] | 0.115 | 0.483 [0.116 - 2.011] | 0.317 |
| Sigmoid                    | 1.374 [0.433 - 4.362] | 0.590 | 1.194 [0.331 - 4.553] | 0.795 |
| Differentiation            |                      |                      |
| Poorly                     | 1 ref.               | 1 ref.               |
| Moderately                 | 0.524 [0.171 - 1.606] | 0.258 | 4.105 [0.896 - 18.811] | 0.069 |
| Well                       | 0.437 [0.146 - 1.313] | 0.140 | 1.245 [0.357 - 4.334] | 0.731 |
| Unknown                    | 0.586 [0.181 - 1.902] | 0.374 | 1.163 [0.332 - 4.075] | 0.814 |
| TNM stage                  |                      |                      |
| I                          | 1 ref.               | 1 ref.               |
| II                         | 1.765 [0.392 - 7.947] | 0.459 | 0.779 [0.147 - 4.121] | 0.769 |
| III                        | 1.778 [0.376 - 8.407] | 0.468 | 0.665 [0.111 - 3.988] | 0.656 |
| IV                         | 3.257 [0.671 - 15.802] | 0.143 | 1.574 [0.256 - 9.675] | 0.625 |
| Family history             |                      |                      |
| No                         | 1 ref.               | 1 ref.               |
| Yes                        | 1.448 [0.675 - 3.110] | 0.342 | 1.313 [0.478 - 3.607] | 0.598 |
| β-catenin                  |                      |                      |
| No                         | 1 ref.               | 1 ref.               |
| Yes                        | 2.586 [1.194 - 5.597] | 0.016 | 3.842 [1.422 - 10.376] | 0.008 |
| MSI status                 |                      |                      |
| MSS                        | 1 ref.               | 1 ref.               |
| MSL                        | 0.697 [0.283 - 1.718] | 0.433 | 0.864 [0.284 - 2.624] | 0.796 |
| MSH                        | 0.792 [0.285 - 2.393] | 0.654 | 0.902 [0.245 - 3.328] | 0.877 |
| Age of diagnose            |                      |                      |
| < 50                       | 1 ref.               | 1 ref.               |
| > 50                       | 1.671 [0.802 - 3.480] | 0.170 | 1.790 [0.703 - 4.559] | 0.223 |

95% confidence interval.
Clarified (16). Wong et al. clearly showed that the expression of beta-catenin may function as a poor prognostic marker for CRC patients. This study showed that the nuclear beta-catenin positive group with rectum tumors had a younger age of diagnosis (P = 0.004) than the nuclear beta-catenin negative group. We observed that the tumors in patients with positive beta-catenin expression were predominantly located in the rectum. Recent papers on beta-catenin indicating its prognostic value have been conflicting; with some studies reporting a good or no prognostic value (10, 11, 16, 22, 23), while others observed poorer clinical outcome in this regard (19, 21). Many issues may explain these contradictory results including intrinsic tumor heterogeneity, different immunohistochemical staining, visualization methods with varying degrees of sensitivity, and lack of standardization of what constitutes a “positive” or “negative” result. In many cases, nuclear beta-catenin expression is mostly seen in the margin and not in the center of the tumor (10).

Although we found no significant association between patients with nuclear beta-catenin positive and negative tumors based on TNM stage, Lugli and colleagues, in one study based on a tissue microarray analysis showed that increased expression of nuclear beta-catenin and loss of membranous E-cadherin were related to tumor and lymph node invasion, the presence of vascular invasion and worse survival (24). Interestingly, Norwood et al. in a recent valuable paper showed that low levels of cytoplasmic beta-catenin expression are associated with reduced survival in CRC patients as well as worse TNM staging in esophageal adenocarcinoma (10).

Our study showed that the nuclear beta-catenin positive group had tumors located predominantly in the rectum site versus other sites and correlated with MSI status. In line with this result, Wangeljord et al. showed that high level of beta-catenin expression was more frequent in rectum and sigmoid tumors and was also associated with MSI screening status (11). In line with our study, Toth et al. reported that patients with dukes B2 stage colorectal tumors and loss of beta-catenin expression were prone to metastatic spread. They also suggested that in Dukes B2 stage rectal cancers the loss of membranous expression of beta-catenin is associated with a distant metastasis development (25).

Another paper by Gomez-Millan et al. in 2013 revealed that nuclear beta-catenin loss of expression was higher in the invasive margin in comparison with the tumor center. They also found that the mRNA levels of beta-catenin are not associ-
ated with prognosis in this study (26). Wanitsuwan et al. revealed that the overall expression of β-catenin showed an association with better differentiation and early stage in CRC. However, they did not find a predictive value for nuclear β-catenin in CRC patients (23). Elzaghel and colleagues postulated that nuclear β-catenin expression provides extra information in predicting patient outcome in advanced CRC stages (27). Jaime Gomez-Millan et al. in 2014 evaluated whether preoperative Chemoradiotherapy (CRT) induces changes in the expression of β-catenin and if these related changes are associated with survival in locally advanced rectal cancer (LARC). In their study they observed that preoperative CRT in related subjects considerably alters the expression of nuclear β-catenin with 49% showing an increased expression after CRT treatment, 17% decreased expression and 34% no change; P = 0.001. They found that patients with overexpressed nuclear β-catenin after CRT treatment showed poor survival in comparison with patients with decreased nuclear β-catenin expression (28). The main limitation of this study was that the expression of β-catenin was assessed by immunohistochemistry (IHC). However, IHC is considered as a low sensitivity method in comparison with other techniques including realtime polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH).

In summary, our findings indicate that nuclear β-catenin expression was associated with MSI status and tumor location in Iranian CRC patients. We also observed an association between nuclear β-catenin expression and poor overall survival. In conclusion, β-catenin nuclear expression is strongly correlated with colorectal carcinogenesis, and can potentially serve as a new prognostic indicator independent of stage and grade. The clinical use of β-catenin as a prognostic factor needs to be investigated in larger patient cohorts.

Acknowledgements

This paper was obtained from the PhD thesis of Ehsan Nazemalhosseini-Mojarad, student at the Gastroenterology and Liver Disease Research Center of Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Authors’ Contributions

Study concept and design: Mahsa Molaei, Ehsan Nazemalhosseini-Mojarad. Lab working, interpreted the clinical data and data collection: Hanieh Mirtalebi, Shohre Almasi, Vahid Chaleshi, Raya Kishani Farahani, Peyman Tarban. Analysis and interpretation of data: Ehsan Nazemalhosseini-Mojarad, Seyed Mohammad Hossein Kashfi. Drafting of the manuscript: Ehsan Nazemalhosseini-Mojarad, Seyed Mohammad Hossein Kashfi. Critical revision of the manuscript for important intellectual content: Peter J.K. Kuppen, Mohammad Reza Zali. Statistical analysis: Ehsan Nazemalhosseini-Mojarad. Administrative, technical, and material support: Mohammad Reza Zali, Study supervision: Ehsan Nazemalhosseini-Mojarad.

Funding/Support

This study was a result of a research project enacted by research institute for gastroenterology and liver disease, Shahid Beheshti university of medical sciences, Tehran, Iran.

References

1. Sung JJY, Lau JYW, Goh KL, Leung WK. Increasing incidence of colorectal cancer in Asia: implications for screening. Oncology. 2005;66(1):371-6.
2. Chaleshi V, Haghighi MM, Savakkar S, Zali N, Vahedi M, Khan-yaghma M, et al. Correlation between the EGFR gene intronic polymorphism, rs2298979, and colorectal cancer. Oncol Lett. 2013;6(4):1079-83.
3. Karami ZA, Saadat AR, JALALIAN HR, ESMAEELI M. Epidemiology and survival analysis of colorectal cancer and its related factors. ROWSAR MED J. 2011.
4. Kashfi SM, Behboudi Farahabkhpsh, F, Golmohammadi M, Nazemalhosseini-Mojarad E, Azinazadeh P, Asadzadeh Aghdaie H. Frameshift Mutations (Deletion at Codon 1309 and Codon 849) in the APC Gene in Iranian FAP Patients: a Case Series and Review of the Literature. Int J Mol Cell Med. 2014;3(3):196-202.
5. Shemirani AI, Haghighi MM, Zadem SM, Fatemi SR, Taleghani MY, Zali N, et al. Simplified MSI marker panel for diagnosis of colorectal cancer. Asian Pac J Cancer Prev. 2011;12(8):2001-4.
6. Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M, Worsavasut-arne J. Molecular pathways in colorectal cancer. J Gastrointestinal Hepatol. 2012;27(9):3425-31.
7. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138(6):2059-72.
8. Clevens H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127(3):469-80.
9. White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers. Gastroenterology. 2012;142(2):219-32.
10. Norwood MG, Bailey N, Nani J, Gillies RS, Nicholson A, Ubhi S, et al. Cytoplasmic beta-catenin accumulation is a good prognostic marker in upper and lower gastrointestinal adenocarcinomas. Histopathology. 2010;57(1):101-11.
11. Wangeljord S, Brandstedt J, Lindquist KE, Nodin B, Jirstrom K, Eberhard J. Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer. Diagn Pathol. 2013;8:10.
12. Stanczak A, Stec R, Bodnar I, Olszewski W, Cichowicz M, Kozlowski W, et al. Prognostic significance of Wnt-1, beta-catenin and E-cadherin expression in advanced colorectal cancer. Pathol Oncol Res. 2011;17(4):595-61.
13. Martensson A, Oberg A, Jung A, Cederquist K, Stenberg R, Palmqvist R. Beta-catenin expression in relation to genetic instability and prognosis in colorectal cancer. Oncol Rep. 2007;17(2):447-52.
14. Han SA, Chun H, Park CM, Kang SJ, Kim SH, Sohn D, et al. Prognostic Significance of beta-catenin in Colorectal Cancer with Liver Metastasis. Clin Oncol. 2005;18(10):761-7.
15. Wong SC, Lo ES, Chan AK, Lee KC, Hisao WL. Nuclear beta catenin as a potential prognostic and diagnostic marker in patients with colorectal cancer from Hong Kong. Mol Pathol. 2003;56(6):347-52.
16. Chung GG, Provost E, Kielhorn EP, Charette LA, Smith BL, Rimml DL. Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis. Clin Cancer Res. 2001;7(12):4013-20.
17. Wong SC, Lo ES, Lee KC, Chan JK, Hisao WL. Prognostic and diagnostic significance of beta-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res. 2000;6(10):4340-8.
18. Ghiari M, Arfaouei A, Kriaa L, Chaar I, Amara S, Lounis MA, et al. The prognostic value of the immunohistochemical expression and mutational pattern of the key mediator of Wnt signaling: beta-catenin in Tunisian patients with colorectal carcinoma. Appl Immunohistochem Mol Morphol. 2012;20(1):62-70.
19. Baldus SE, Monig SP, Huxel S, Landsberg S, Hanisch FG, Engelmann K, et al. MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. *Clin Cancer Res.* 2004;10(8):2790–6.

20. Miyamoto S, Endoh Y, Hasebe T, Ishii G, Kodama K, Goya M, et al. Nuclear beta-catenin accumulation as a prognostic factor in Dukes’ D human colorectal cancers. *Oncol Rep.* 2004;12(2):245–51.

21. Chen Z, He X, Jia M, Liu Y, Qu D, Wu D, et al. Beta-catenin overexpression in the nucleus predicts poor disease and unfavorable survival in colorectal cancer: a meta-analysis. *PloS One.* 2011;6(5):e18564.

22. Horst D, Reu S, Kriegl I, Engel J, Kirchner T, Jung A. The intratumoral distribution of nuclear beta-catenin is a prognostic marker in colon cancer. *Cancer.* 2009;115(10):2063–70.

23. Wanitsuwan W, Kannungo S, Boonpipattanapong T, Sangthong R, Sangkhathat S. Overall expression of beta-catenin outperforms its nuclear accumulation in predicting outcomes of colorectal cancers. *World J Gastroenterol.* 2008;14(39):6052–9.

24. Lugli A, Zlobec I, Minoo P, Baker K, Tornillo L, Terracciano I, et al. Prognostic significance of the Wnt signalling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: a tissue microarray-based analysis. *Histopathology.* 2007;50(4):453–64.

25. Toth I, Andras C, Molnar C, Tanyi M, Csiki Z, Molnar P, et al. Investigation of beta-catenin and E-cadherin expression in Dukes’ B2 stage colorectal cancer with tissue microarray method. Is it a marker of metastatic potential in rectal cancer? *Pathol Oncol Res.* 2012;18(2):429–37.

26. Gomez-Millan J, Perez L, Arias I, Del Mar Delgado M, De Luque V, Roman A, et al. Preoperative chemoradiotherapy in rectal cancer induces changes in the expression of nuclear beta-catenin: prognostic significance. *BMC Cancer.* 2014;14:392.

27. Elzagheid A, Buhmeida A, Korkeila E, Collan Y, Syrjanen K, Pyrhonen S. Nuclear beta-catenin expression as a prognostic factor in advanced colorectal carcinoma. *World J Gastroenterol.* 2008;14(24):3866–71.

28. Lee SJ, Choi SY, Kim WJ, Ji M, Lee TG, Son BR, et al. Combined aberrant expression of E-cadherin and S100A4, but not beta-catenin is associated with disease-free survival and overall survival in colorectal cancer patients. *Diagn Pathol.* 2013;8:99.